Recurrent Endometrial Clear Cell Adenocarcinoma
5
1
3
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
20.0%
1 terminated out of 5 trials
0.0%
-86.5% vs benchmark
20%
1 trials in Phase 3/4
0%
3 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (5)
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer